Palisade Bio Future Growth

Future criteria checks 0/6

Palisade Bio's earnings are forecast to decline at 18.7% per annum. EPS is expected to grow by 4.6% per annum.

Key information

-18.7%

Earnings growth rate

4.6%

EPS growth rate

Pharmaceuticals earnings growth	21.2%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	Low
Last updated	29 May 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:7NS0 - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	N/A	-24	N/A	N/A	2
12/31/2025	N/A	-20	N/A	N/A	2
12/31/2024	N/A	-15	N/A	N/A	2
3/31/2024	N/A	-14	-11	-11	N/A
12/31/2023	0	-12	-11	-11	N/A
9/30/2023	0	-13	-12	-12	N/A
6/30/2023	0	-14	-12	-12	N/A
3/31/2023	0	-13	-13	-13	N/A
12/31/2022	N/A	-15	-13	-13	N/A
9/30/2022	N/A	-9	-13	-13	N/A
6/30/2022	N/A	0	-13	-13	N/A
3/31/2022	N/A	-27	-17	-17	N/A
12/31/2021	N/A	-27	-15	-15	N/A
9/30/2021	N/A	-32	-13	-13	N/A
6/30/2021	N/A	-39	-11	-11	N/A
3/31/2021	N/A	-12	-5	-5	N/A
12/31/2020	N/A	-10	-5	-5	N/A
9/30/2020	N/A	-9	-5	-5	N/A
12/31/2019	N/A	-10	-7	-7	N/A
12/31/2018	1	-4	-2	-2	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 7NS0 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 7NS0 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 7NS0 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if 7NS0's revenue is forecast to grow faster than the German market.

High Growth Revenue: 7NS0 is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 7NS0's Return on Equity is forecast to be high in 3 years time

Palisade Bio Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis

Palisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (UC)

Palisade Bio, Inc. Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis

Palisade Bio, Inc. has filed a Follow-on Equity Offering.

Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis

Palisade Bio Reports Data Demonstrating PDE4B Expression in Patient Cohorts Could Be Utilized as a Potential Marker for Patient Stratification

Palisade Bio, Inc. Selects Dose for Upcoming Phase 1 Clinical Study of PALI-2108 for Ulcerative Colitis

Palisade Bio, Inc. Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Leading Product Candidate, PALI-2108

Palisade Bio, Inc. Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product

Palisade Bio, Inc., Annual General Meeting, Jul 08, 2024

Palisade Bio, Inc. Announces Presentation of Positive Preclinical Data from PALI-2108

Palisade Bio, Inc. announced that it has received $3.999943 million in funding

Palisade Bio, Inc. Appoints Margery Fischbein to Its Board of Directors

Palisade Bio, Inc. announced that it expects to receive $3.999996 million in funding

Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS)

Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool

Palisade Bio, Inc. Receives Notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC Regarding Non-Compliance with the Audit Committee Requirements

Palisade Bio, Inc. Announces Advisory Board Appointments

New major risk - Share price stability

Palisade Bio, Inc. has withdrawn its Follow-on Equity Offering in the amount of $5 million.

Palisade Bio, Inc. has filed a Follow-on Equity Offering in the amount of $5 million.

Palisade Bio, Inc. has filed a Follow-on Equity Offering in the amount of $5 million.

New major risk - Revenue and earnings growth

Palisade Bio Receives Non-Compliance Notice from Nasdaq

Palisade Bio, Inc. has completed a Follow-on Equity Offering in the amount of $1.965094 million.

Palisade Bio, Inc. has completed a Follow-on Equity Offering in the amount of $1.965094 million.

New major risk - Market cap size

Palisade Bio, Inc. Announces Topline Results from U.S. Phase 2 Profile Study Evaluating LB1148 for Post-Surgical Abdominal Adhesions

Palisade Bio, Inc. Announces Enrollment and Dosing of First Patient in LB1148 Dose Optimization Study

Palisade Bio, Inc. Announces Board Appointments

Palisade Bio, Inc. has completed a Follow-on Equity Offering in the amount of $1.220371 million.

Palisade Bio, Inc. announced that it has received funding

Palisade Bio Regains Compliance with Nasdaq Listing Requirements

U.S. Food and Drug Administration Grants Fast Track Designation to Palisade Bio for LB1148 for Accelerated Return of Bowel Function Following GI Surgery

Palisade Bio Appoints Herbert B. Slade MD, FAAAAI as Chief Medical Officer

Palisade Bio, Inc. Terminates Michael Dawson as Chief Medical Officer

Palisade Bio, Inc. Announces Executive Changes

Palisade Bio, Inc. Announces Chief Executive Officer Transition

Palisade Bio Announces Oral Presentation of Phase 2 Data at the American College of Surgeons Clinical Congress 2022

Palisade Bio, Inc. Announces the Commencement of Patient Enrollment and Dosing in Its Pivotal Phase 3 Study Evaluating LB1148

Palisade Bio Announces First Patient Enrolled and Dosed in Pivotal Phase 3 Study Evaluating LB1148 for Postoperative Return of Bowel Function

Palisade Bio, Inc. has completed a Composite Units Offering in the amount of $12 million.

Palisade Bio, Inc. Announces First Patient Screened in Phase 3 Study Evaluating LB1148 for Postoperative Return of Bowel Function

Palisade Bio Initiates Phase 3 Study of Lb1148 in Lead Indication for Postoperative Return of Bowel Function

Palisade Bio, Inc. Receives Notice of Delisting or Failure to Satisfy Continued Listing Rule or Standard

Palisade Bio, Inc. announced a financing transaction

Palisade Bio, Inc. and Newsoara Biopharma Co., Ltd. Receives NMPA Clearance to Commence Phase 3 Clinical Trial in China Evaluating LB1148

High number of new directors

Palisade Bio, Inc., Annual General Meeting, Jun 09, 2022

Palisade Bio, Inc. Appoints Robert McRae as Senior Vice President, Operations and Strategic Development

Palisade Bio to Announce Adhesions Clinical Data at SAGES 2022 Annual Meeting

High number of new and inexperienced directors

Palisade Bio, Inc. announced that it has received $5.209141 million in funding from Yuma Regional Medical Center

Palisade Bio, Inc. announced delayed 10-Q filing

Palisade Bio Receives FDA Fast Track Designation for LB1148 for Reduction of Adhesions Following Abdominal and Pelvic Surgery

Palisade Bio and Newsoara Announce Completion of Phase 2 Study in GI Surgery Study in China

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies